Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Core Insights - Adaptive Biotechnologies Corporation is showcasing the increasing interventional use of its clonoSEQ® test at the 67th American Society of Hematology Annual Meeting, with 90 abstracts featuring clonoSEQ data [1] - The clonoSEQ test is being utilized to guide clinical decisions in blood cancer treatment, particularly in assessing measurable residual disease (MRD) status [3][8] Group 1: Clinical Studies and Findings - The phase II EndRAD study supports the use of next-generation sequencing (NGS) MRD status prior to allogeneic hematopoietic cell transplantation (HCT) to select non-total body irradiation (TBI) conditioning approaches, showing excellent event-free and overall survival in 51 NGS MRD negative patients [2] - In multiple myeloma (MM), a phase III AURIGA study demonstrated that deep MRD responses correlate with improved progression-free survival, with intensified maintenance post-transplant doubling MRD negativity rates [7] - A phase II study in chronic lymphocytic leukemia (CLL) showed that a combination therapy achieved deep and durable remissions based on MRD assessment, highlighting clonoSEQ's role in guiding treatment duration [7] Group 2: Impact on Treatment Approaches - clonoSEQ MRD status is being used by healthcare providers to tailor treatment intensity and duration, enhancing precision in clinical decision-making [3][8] - The data presented at ASH indicates a shift towards using clonoSEQ to de-escalate therapy in certain patient populations, such as frail older adults with diffuse large B-cell lymphoma (DLBCL) [7] - The unprecedented volume of data at ASH reinforces clonoSEQ's leadership in blood cancer MRD monitoring, reflecting its value in therapeutic progress and patient management [8] Group 3: Product Overview - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia [9] - The test identifies and quantifies DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, which aids clinicians in monitoring MRD with precision [10] - clonoSEQ is covered by Medicare for multiple myeloma, CLL, ALL, DLBCL, and mantle cell lymphoma, indicating its established role in clinical practice [9]